Please assess the completion status of the following clinical trial:

Trial Title: Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed melanoma~  * Unresectable stage IV disease~ * Mucosal and unknown primary disease allowed~* Measurable disease, defined as at least one lesion that can be measured in at least one dimension as ≥ 20 mm (or as ≥ 10 mm if the CT slice thickness is ≤ 5 mm)~  * Measurable lesion must be outside a previously treated area~* Must have 1 paraffin block of primary tumor and/or metastatic tissue available for analysis of MGMT~* No ocular melanoma~* No bleeding skin metastases~* No CNS metastases (even if previously treated) by brain MRI~PATIENT CHARACTERISTICS:~* WHO performance status 0-2~* ANC ≥ 1.5 x 10\^9/L~* Platelet count ≥ 100 x 10\^9/L~* Hemoglobin ≥ 90 g/L (transfusion allowed)~* Serum total bilirubin ≤ 1.5 times upper limit of normal (ULN)~* ALT and alkaline phosphatase ≤ 2.5 times ULN (5 times ULN in patients with liver metastases)~* Serum creatinine \< 177 μmol/L~* Proteinuria \< 2+ by urine dipstick OR urine protein ≤ 1 g by 24-hour urine collection~* INR ≤ 1.5~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 12 months after completion of study treatment~* No other primary tumors within the past 5 years, except adequately controlled limited basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No history or evidence of CNS disease unrelated to cancer (e.g., uncontrolled seizures) by physical/neurological examination, unless adequately treated with standard medical therapy~* No frequent vomiting or any other pre-existing medical condition that would preclude swallowing and/or absorption of oral medication~* No history or evidence of inherited bleeding diathesis or coagulopathy with risk of bleeding~* No uncontrolled hypertension (i.e., systolic blood pressure \> 150 mm Hg and/or diastolic blood pressure \> 100 mm Hg, measured repeatedly, despite adequate treatment with at least two different antihypertensive drugs)~* No clinically significant (i.e., active) cardiovascular disease, including any of the following:~  * Cerebrovascular accident/stroke or myocardial infarction within the past 6 months~ * Unstable angina~ * New York Heart Association (NYHA) class II or greater congestive heart failure~ * Serious cardiac arrhythmia (i.e., ventricular arrhythmia, high-grade atrioventricular-block) that requires medication during the study, interferes with regularity of the study treatment, or is uncontrolled by medication~* No serious non-healing wound, active peptic ulcer, or non-healing bone fracture~* No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months~* No significant traumatic injury within the past 30 days~* No uncontrolled active infection~* No known HIV infection~* No known hypersensitivity to any of the study drugs or excipients~* No evidence of any other disease, metabolic or psychological dysfunction, psychiatric disorder, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, or that may affect patient compliance with study routines, or places the patient at high risk from treatment-related complications~PRIOR CONCURRENT THERAPY:~* At least 4 weeks since prior adjuvant cytokine therapy (e.g., interleukin, interferon) or vaccine therapy and recovered~  * Prior vaccine therapy for stage IV disease allowed~* Prior perfusion therapy (limb and liver) for loco-regional disease allowed~* No prior chemotherapy for metastatic disease~* No prior bevacizumab or other angiogenic inhibitors~* No prior radiotherapy to lesion(s) selected for measurement~* More than 30 days since prior treatment in a clinical trial~* More than 30 days since prior major surgery with high risk of bleeding~* More than 24 hours since prior minor surgery~* More than 10 days since prior and no concurrent full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes~  * Prophylactic use of anticoagulants is allowed (e.g., maintenance of venous catheter)~* More than 10 days since prior and no concurrent acetylsalicylic acid (\> 325 mg/day) or clopidogrel (\> 75 mg/day)~* No other concurrent non-steroidal anti-inflammatory drugs (NSAIDs)~* No concurrent dipyridamole~* No concurrent major surgery~* No concurrent radiotherapy to the target lesions~* No other concurrent experimental drugs or anticancer therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination Therapy Temozolomide & Bevacizumab (Type: EXPERIMENTAL): Combination therapy~* Temozolomide 150 mg/m2 p.o., days 1-7, repeated every 14 days~* Bevacizumab 10 mg/kg i.v., day 1, repeated every 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).